Workflow
证券调查
icon
Search documents
RCI ALERT: Bragar Eagel & Squire, P.C. is Investigating RCI Hospitality Holdings, Inc. on Behalf of RCI Stockholders and Encourages Investors to Contact the Firm
Globenewswire· 2025-09-17 22:15
Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against RCI Hospitality Holdings, Inc. due to allegations of violations of federal securities laws and unlawful business practices [1][2]. Investigation Details - The investigation centers on whether RCI issued false or misleading statements and failed to disclose important information to investors [2]. - A Reuters report indicated that RCI and five executives were indicted for their involvement in a 13-year bribery scheme to evade millions in New York sales taxes, leading to a share price drop of over 15.9% on the day of the news [2]. Next Steps - Investors who purchased RCI shares and experienced losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims [3]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation across the United States [4].
RXSIGHT ALERT: Bragar Eagel & Squire, P.C.Announces Investigation into RxSight, Inc. (RXST) and Encourages Investors to Contact the Firm
GlobeNewswire News Room· 2025-07-16 01:00
Core Insights - RxSight, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices following a significant drop in stock price and revised revenue guidance [2][3]. Financial Performance - For Q2 2025, RxSight reported expected revenue of $33.6 million, which is a decrease of 4% year-over-year and a decrease of 11% compared to Q1 2025 [3]. - The company revised its 2025 revenue guidance, lowering the midpoint from $167.5 million to $125 million [3]. Market Reaction - Following the announcements regarding financial results and guidance, RxSight's stock price fell by $4.84 per share, or 37.84%, closing at $7.95 per share on July 9, 2025 [3]. Analyst Actions - Wells Fargo and BTIG downgraded RxSight's stock, citing "structural issues" and a challenging competitive environment [3].